Camille Abboud
Blood and Marrow Transplant & Cellular/Gene Therapy Specialist, Hematologic Oncologist, Medical Oncologist · Alvin J. Siteman Cancer Center
Credentials: · · · · ·
History
Hematology
Medical Oncology
Internal Medicine
Research
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified
Cancer Research · 1993 · 1,034 citations
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
New England Journal of Medicine · 2016 · 716 citations
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2017 · 339 citations
73 papers · 4 as a resident
- PW
49 papers
47 papers · 5 as a fellow
43 papers
42 papers · 1 as a fellow
40 papers
36 papers
28 papers
Grants
- 2013–2018
Specialized Program of Research Excellence (SPORE) in Leukemia
National Cancer Institute · P50
Project lead · $529.3K · Washington University
- 1993–1998
Expansion of Progenitors in Breast Cancer
National Cancer Institute · R01
Contact PI · $756.6K · University of Rochester
- 1997
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $20.2K · University of Rochester
- 1991–1994
In-vitro and In-vivo Effects of Gm-Csf on Adult Anll
National Cancer Institute · R03
Contact PI · $126.5K · University of Rochester
Clinical trials
- 2017–2020
Principal investigator · Withdrawn · Phase 1
Washington University School of Medicine
- 2014–2016
Principal investigator · Completed · Phase 2
Washington University School of Medicine
- 2010–2012
Principal investigator · Completed · Phase 1
Washington University School of Medicine
- 2009–2014
Oral Clofarabine for Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1
Washington University School of Medicine